ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
3.510
-0.080 (-2.23%)
Nov 17, 2026, 9:30 AM EST - Market open
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, ARS Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $17. The average 1-year stock price forecast is 384.33% higher than the current stock price, while the lowest is $14 (+298.86%) and the highest is $20 (+469.80%).
Price Target: $17 (+384.33%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 → $20 | Buy | Reiterates | $30 → $20 | +469.80% | Nov 6, 2026 |
| Raymond James | Raymond James | Buy Maintains $28 → $17 | Buy | Maintains | $28 → $17 | +384.33% | Nov 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $18 → $15 | Buy | Maintains | $18 → $15 | +327.35% | Sep 8, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 14, 2026 |
Financial Forecast
Revenue This Year
121.30M
from 84.28M
Increased by 43.93%
Revenue Next Year
172.89M
from 121.30M
Increased by 42.53%
EPS This Year
-1.88
from -1.74
EPS Next Year
-0.90
from -1.88
EPS and Forward PE are based on non-GAAP adjusted numbers.